Decoding pharmacogenomic test interpretation and application to patient care
Authors:
- Roseann S. DonnellyRDRoseann S. Donnelly
- Larisa H. CavallariLCLarisa H. Cavallari
- Jeannine S. McCuneJMJeannine S. McCune
- Jennifer Trofe‐ClarkJTJennifer Trofe‐Clark
- Christine M. FormeaCFChristine M. Formea
- Glenda HoffeckerGHGlenda Hoffecker
- Keri C. AndersonKAKeri C. Anderson
- Shubha BhatSBShubha Bhat
- Scott A. MosleySMScott A. Mosley
- Qing MaQMQing Ma
- Ariel FerdockAFAriel Ferdock
Open Access
- 8 May 2024
- journal article
- editorial
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (6) , 581-588
Abstract
Pharmacogenomics is a growing area of medicine, and pharmacists across clinical practice settings have the opportunity to individualize medication selection and dosing using genetic data. However, many practicing pharmacists may feel ill‐equipped to interpret pharmacogenomic test results because of insufficient education and training. Evidence‐based, updated, and freely available resources such as the Clinical Pharmacogenetics Implementation Consortium guidelines can help pharmacists interpret and apply pharmacogenomic test results to patient care. Although gaps for the application of pharmacogenomic information exist, this commentary aims to demystify the interpretation of pharmacogenomic test results and empower pharmacists to apply genetic data alongside other clinical variables to optimize medication‐related outcomes for their patients. An “ABCD” framework is proposed to guide pharmacists through the steps: (1) Actionability—Are the gene(s) clinically relevant for the patient? (2) Be Mindful of Limitations—What are the caveats with pharmacogenomic test results and reports? (3) Clinical Practice Guidelines—How do you use pharmacogenomic test results to guide clinical decision‐making? and (4) Document and Discuss—How do you educate the patient about their pharmacogenomic test results and document the results for future use? Key concepts are illustrated using a psychiatric patient case example.Keywords
This publication has 46 references indexed in Scilit:
- Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric PatientsJAMA Network Open, 2020
- Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy UsersJAMA Network Open, 2019
- Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic ResearchClinical Pharmacology & Therapeutics, 2018
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S GenotypesClinical Pharmacology & Therapeutics, 2018
- Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and ProjectsClinical Pharmacology & Therapeutics, 2018
- Clinical Pharmacogenetics Implementation Consortium Guideline forHLAGenotype and Use of Carbamazepine and Oxcarbazepine: 2017 UpdateClinical Pharmacology & Therapeutics, 2018
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen TherapyClinical Pharmacology & Therapeutics, 2018
- Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet TherapyClinical Pharmacology & Therapeutics, 2017
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus DosingClinical Pharmacology & Therapeutics, 2015
- PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogeneticsAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2014